JP2014506919A - クロピドグレル硫酸水素塩の球状粒子、これを含む薬学的組成物及びその製造方法 - Google Patents
クロピドグレル硫酸水素塩の球状粒子、これを含む薬学的組成物及びその製造方法 Download PDFInfo
- Publication number
- JP2014506919A JP2014506919A JP2013556533A JP2013556533A JP2014506919A JP 2014506919 A JP2014506919 A JP 2014506919A JP 2013556533 A JP2013556533 A JP 2013556533A JP 2013556533 A JP2013556533 A JP 2013556533A JP 2014506919 A JP2014506919 A JP 2014506919A
- Authority
- JP
- Japan
- Prior art keywords
- clopidogrel hydrogensulfate
- clopidogrel
- spherical particles
- tablet
- hydrogensulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 title claims abstract description 85
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 239000012798 spherical particle Substances 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000002245 particle Substances 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 57
- 238000009702 powder compression Methods 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000000314 lubricant Substances 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000011230 binding agent Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000013078 crystal Substances 0.000 abstract description 43
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 230000009466 transformation Effects 0.000 abstract description 5
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 4
- -1 poor compressibility Chemical compound 0.000 abstract description 4
- 230000002785 anti-thrombosis Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 35
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 31
- 229960003009 clopidogrel Drugs 0.000 description 29
- 239000000843 powder Substances 0.000 description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 239000012458 free base Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 238000002845 discoloration Methods 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940020573 plavix Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003958 clopidogrel bisulfate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【選択図】図1
Description
2)前記溶液にクロピドグレル種結晶を添加する段階;
3)前記溶液に、シクロヘキサンに希釈された硫酸を滴加する段階;
4)前記混合溶液を撹拌して球状粒子を製造する段階;及び
5)前記粒子をろ過、洗浄及び乾燥して球状粒子を収得する段階。
<1−1>クロピドグレル遊離塩基の製造
554g(1.0モル)のクロピドグレル(1R)−(−)−カンファー−10−スルホン酸塩をジクロロメタン300mLに添加した後、炭酸カリウム138.3gを水300mLに溶かして添加した。前記混合物を30分間撹拌した後で層分離し、無水硫酸ナトリウムで脱水させた後、ろ過及び減圧濃縮してオイル相のクロピドグレル遊離塩基318.6g(収率99%)を得た。
クロピドグレル遊離塩基200gを2−ブタノール2,000mLに溶かして26〜28℃に維持し、結晶形I型の種結晶(クロピドグレル有機塩基の量に対して5〜20%)を投入した。その後、98%硫酸62.3gをシクロヘキサン400mLに希釈し、温度を0.5〜2℃に下げながら8時間〜10時間にわたってゆっくり滴加した。滴加が完了した後の温度は17〜19℃に調節した。滴加が完了した後、30分〜1時間後に球状結晶をろ過した。ろ過した結晶を70〜80℃で24時間乾燥し、258g(収率95%)の結晶形I型の球状粒子を得た。
実施例<1−1>で得たクロピドグレル遊離塩基200gをエチルアセテート2,000mLに溶かして26〜28℃に維持し、その後、98%硫酸62.3gをシクロヘキサン400mLに希釈して1時間滴加した後、20〜25℃の温度で10〜12時間にわたって激しく撹拌した。生成されたクロピドグレル粉末状結晶をろ過した。ろ過した結晶を70〜80℃で24時間真空乾燥し、240g(収率92%)の結晶形I型の粉末状粒子を得た。
実施例<1−1>で得たクロピドグレル遊離塩基200gを2−プロパノール2,000mLに溶かして26〜28℃に維持し、その後、98%硫酸62.3gをシクロヘキサン400mLに希釈して3時間滴加した後、18〜20℃の温度で6時間にわたって激しく撹拌した。生成されたクロピドグレル粉末状結晶をろ過した。ろ過した結晶を70〜80℃で24時間真空乾燥し、250g(収率94%)の結晶形I型の粉末状粒子を得た。
実施例1、比較例1及び2で製造された粒子を対象にして、レーザー回折法による粒度測定機(Mastersizer 2000(登録商標)、Malvern)を使用して粒度分布を測定し、試料は、乾式モジュール(Scirocco 2000(登録商標)、Malvern)を使用して1barの圧力で注入した。それぞれの粒子の10%体積粒径(d0.1)、50%体積粒径(d0.5)及び90%体積粒径(d0.1)を測定し、下記の表1に示した。
実施例1で製造されたクロピドグレル硫酸水素塩の球状粒子(結晶形I型)を用いて直接粉末圧縮法と湿式顆粒法で裸錠を製造し、製造過程中に変色又は不純物増加の発生有無を比較し、製造された裸錠をペトリディッシュに入れて加速試験条件(温度:40±2℃、相対湿度:75±5%)に露出して保管しながら、米国薬局方のクロピドグレル硫酸水素塩錠剤(Clopidogrel Bisulfate Tablet)項の試験方法によって含量及び純度試験を行い、安定性を比較した。
下記の表4の組成により、実施例1で製造されたクロピドグレル硫酸水素塩I型の球状粒子を用いて錠剤を製造した。
下記の表5の組成に従って、比較例1及び2で製造されたクロピドグレル硫酸水素塩の粉末(結晶形I)を用いて錠剤を製造した。
前記実施例2〜4と比較例3〜8で打錠を実施しながら、スティッキングなどの打錠障害の発生有無を確認し、打錠された錠剤30錠を用いて大韓薬典の一般試験法のうち重量偏差試験法によって試験し、判定値を算出した。また、硬度測定機を使用して錠剤の強度を測定した。前記測定結果を下記の表6に示した。
前記実施例2で製造された本発明の錠剤と従来の市販中のプラビックス錠(Plavix、Sanofi−Aventis)をペトリディッシュに入れ、加速試験条件(温度:40±2℃、相対湿度:75±5%)に露出して保管しながら、米国薬局方のクロピドグレル硫酸水素塩錠剤項の試験方法によって含量及び純度試験を行い、安定性を比較した。測定結果を下記の表7に示した。
前記実施例2で製造された本発明の錠剤をポリエチレン材質の瓶にシリカゲルと共に包装し、加速条件である40℃/相対湿度75%で保管しながら米国薬局方に収載されたClopidogrel Bisulfate Tablet項によって試験し、6ヶ月間の安定性を評価した。測定結果を下記の表8に示した。
Claims (6)
- 30μm以上の10%体積粒径(d0.1)及び50〜200μm範囲の50%体積粒径(d0.5)を有するクロピドグレル硫酸水素塩の球状粒子。
- 前記クロピドグレル硫酸水素塩が結晶形I型、結晶形II型、又はその混合物であることを特徴とする、請求項1に記載のクロピドグレル硫酸水素塩の球状粒子。
- 請求項1のクロピドグレル硫酸水素塩の球状粒子;
薬学的に許容可能な直打用賦形剤;
崩解剤として低置換度ヒドロキシプロピルセルロース;
流動化剤としてコロイド性二酸化ケイ素;及び
滑沢剤としてフマル酸ステアリルナトリウムを含む薬学的組成物。 - 前記薬学的組成物が結合剤を含有しないことを特徴とする、請求項3に記載の薬学的組成物。
- 請求項3の薬学的組成物から直接粉末圧縮法によって製造される錠剤。
- 1)請求項1のクロピドグレル硫酸水素塩の球状粒子;薬学的に許容可能な直打用賦形剤;崩解剤として低置換度ヒドロキシプロピルセルロース;流動化剤としてコロイド性二酸化ケイ素;及び滑沢剤としてフマル酸ステアリルナトリウムを混合する段階;及び
2)前記混合物に追加の結合剤を加えず、直接粉末圧縮法によって裸錠を形成する段階を含む、クロピドグレル硫酸水素塩の球状粒子を含有する錠剤の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0069039 | 2011-07-12 | ||
KR1020110069039A KR101324862B1 (ko) | 2011-07-12 | 2011-07-12 | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
PCT/KR2011/008071 WO2013008981A1 (ko) | 2011-07-12 | 2011-10-27 | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014506919A true JP2014506919A (ja) | 2014-03-20 |
Family
ID=47506246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013556533A Pending JP2014506919A (ja) | 2011-07-12 | 2011-10-27 | クロピドグレル硫酸水素塩の球状粒子、これを含む薬学的組成物及びその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140154330A1 (ja) |
EP (1) | EP2732810A1 (ja) |
JP (1) | JP2014506919A (ja) |
KR (1) | KR101324862B1 (ja) |
CN (1) | CN103717207A (ja) |
BR (1) | BR112014000814A2 (ja) |
MA (1) | MA35264B1 (ja) |
WO (1) | WO2013008981A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104817571B (zh) * | 2014-12-31 | 2016-04-20 | 天津大学 | 一种制备球形硫酸氢氯吡格雷i晶型的方法 |
KR101710922B1 (ko) | 2015-06-03 | 2017-02-28 | 경동제약 주식회사 | 클로피도그렐 황산염 결정형 i형의 제조방법 |
CN105012298B (zh) * | 2015-07-17 | 2016-06-01 | 深圳信立泰药业股份有限公司 | 一种含有球形硫酸氢氯吡格雷i晶型的药物组合物及其制备方法 |
CN105748419B (zh) * | 2015-07-17 | 2018-09-14 | 深圳信立泰药业股份有限公司 | 一种含有球形硫酸氢氯吡格雷i晶型的药物组合物及其制备方法 |
CN105061459B (zh) * | 2015-07-21 | 2016-08-24 | 深圳信立泰药业股份有限公司 | 一种硫酸氢氯吡格雷i晶型球形结晶的制备方法 |
KR102532121B1 (ko) * | 2017-10-18 | 2023-05-12 | 고려제약주식회사 | 돌미나리 추출물 및 항혈전제를 포함하는 항혈전용 조성물 |
US11478432B2 (en) | 2018-04-16 | 2022-10-25 | Jiangsu Vcare Pharma Tech Co., Ltd. | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor |
CN109096302A (zh) * | 2018-07-27 | 2018-12-28 | 天津大学 | 球形硫酸氢氯吡格雷ii晶型及制备方法 |
WO2021261837A1 (ko) * | 2020-06-24 | 2021-12-30 | 뉴지랩파마 주식회사 | 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물 |
CN114369100B (zh) * | 2021-12-15 | 2023-06-20 | 浙江车头制药股份有限公司 | 一种硫酸氢氯吡格雷球形晶型i的制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58144385A (ja) * | 1982-02-22 | 1983-08-27 | Yoshiaki Kawashima | 球状アミノフイリンの製造法 |
JPS59167536A (ja) * | 1983-02-28 | 1984-09-21 | ジ・アツプジヨン・カンパニ− | イブプロフエンの結晶化法 |
JPH05505386A (ja) * | 1990-04-04 | 1993-08-12 | クノル アクチェンゲゼルシャフト | β―フェニルプロピオフェノンの単結晶 |
JP2002518399A (ja) * | 1998-06-15 | 2002-06-25 | サノフィ−サンテラボ | 多形クロピドグレル硫酸水素塩フォーム |
JP2003507484A (ja) * | 1999-08-26 | 2003-02-25 | アベンティス ファルマ ソシエテ アノニム | テリスロマイシンの球形凝集体、その製造方法及びその製薬用剤形の製造への使用 |
JP2005519076A (ja) * | 2002-02-15 | 2005-06-30 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態i、viiiおよびixの新規調製方法 |
JP2006500337A (ja) * | 2002-07-26 | 2006-01-05 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 塩酸ベナゼプリルの結晶多形形態および非晶質形態 |
JP2007508240A (ja) * | 2003-07-22 | 2007-04-05 | バクスター・インターナショナル・インコーポレイテッド | 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法 |
WO2011052940A2 (ko) * | 2009-10-29 | 2011-05-05 | 동아제약주식회사 | 클로피도그랠 황산수소염 ⅰ형 제조방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212954A (zh) * | 2005-05-10 | 2008-07-02 | 伊兰制药国际有限公司 | 纳米粒氯吡格雷制剂 |
EP1742285A1 (de) * | 2005-07-04 | 2007-01-10 | CEKA Elektrowerkzeuge AG + Co. KG | Flussfeldplatte, Brennstoffzelle und Brennstoffzellenstapel |
KR20070009851A (ko) * | 2005-07-14 | 2007-01-19 | 씨제이 주식회사 | 클로피도그렐 황산수소염 함유 약학 조성물 |
KR20070044323A (ko) * | 2005-10-24 | 2007-04-27 | 에스케이케미칼주식회사 | 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제 |
KR100809903B1 (ko) * | 2006-09-05 | 2008-03-06 | 주식회사유한양행 | 안정화된 클로피도그렐-함유 입자, 그의 제조방법, 및 이를포함하는 약학 조성물 |
WO2008122994A2 (en) * | 2007-04-09 | 2008-10-16 | Usv Limited | Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof |
KR101464482B1 (ko) * | 2007-05-08 | 2014-11-26 | 경동제약 주식회사 | 클로피도그렐 황산수소염을 함유하는 약학적 조성물 및 그제조방법 |
KR20090092106A (ko) * | 2008-02-26 | 2009-08-31 | 주식회사 대희화학 | 클로피도그렐 황산수소염을 포함하는 정제 |
CN101721410B (zh) * | 2008-10-30 | 2012-01-25 | 南京正大天晴制药有限公司 | 硫酸氢氯吡格雷的固体药物组合物 |
CN101851247B (zh) * | 2010-06-04 | 2013-05-29 | 浙江华海药业股份有限公司 | 含有硫酸氢氯吡格雷晶体颗粒的组合物 |
-
2011
- 2011-07-12 KR KR1020110069039A patent/KR101324862B1/ko active IP Right Grant
- 2011-10-27 CN CN201180072203.6A patent/CN103717207A/zh active Pending
- 2011-10-27 JP JP2013556533A patent/JP2014506919A/ja active Pending
- 2011-10-27 EP EP11869405.8A patent/EP2732810A1/en not_active Withdrawn
- 2011-10-27 WO PCT/KR2011/008071 patent/WO2013008981A1/ko active Application Filing
- 2011-10-27 BR BR112014000814A patent/BR112014000814A2/pt not_active IP Right Cessation
- 2011-10-27 US US14/131,907 patent/US20140154330A1/en not_active Abandoned
-
2014
- 2014-01-08 MA MA36661A patent/MA35264B1/fr unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58144385A (ja) * | 1982-02-22 | 1983-08-27 | Yoshiaki Kawashima | 球状アミノフイリンの製造法 |
JPS59167536A (ja) * | 1983-02-28 | 1984-09-21 | ジ・アツプジヨン・カンパニ− | イブプロフエンの結晶化法 |
JPH05505386A (ja) * | 1990-04-04 | 1993-08-12 | クノル アクチェンゲゼルシャフト | β―フェニルプロピオフェノンの単結晶 |
JP2002518399A (ja) * | 1998-06-15 | 2002-06-25 | サノフィ−サンテラボ | 多形クロピドグレル硫酸水素塩フォーム |
JP2003507484A (ja) * | 1999-08-26 | 2003-02-25 | アベンティス ファルマ ソシエテ アノニム | テリスロマイシンの球形凝集体、その製造方法及びその製薬用剤形の製造への使用 |
JP2005519076A (ja) * | 2002-02-15 | 2005-06-30 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態i、viiiおよびixの新規調製方法 |
JP2006500337A (ja) * | 2002-07-26 | 2006-01-05 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | 塩酸ベナゼプリルの結晶多形形態および非晶質形態 |
JP2007508240A (ja) * | 2003-07-22 | 2007-04-05 | バクスター・インターナショナル・インコーポレイテッド | 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法 |
WO2011052940A2 (ko) * | 2009-10-29 | 2011-05-05 | 동아제약주식회사 | 클로피도그랠 황산수소염 ⅰ형 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
MA35264B1 (fr) | 2014-07-03 |
EP2732810A1 (en) | 2014-05-21 |
WO2013008981A1 (ko) | 2013-01-17 |
KR101324862B1 (ko) | 2013-11-01 |
BR112014000814A2 (pt) | 2017-02-21 |
CN103717207A (zh) | 2014-04-09 |
KR20130010098A (ko) | 2013-01-25 |
US20140154330A1 (en) | 2014-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014506919A (ja) | クロピドグレル硫酸水素塩の球状粒子、これを含む薬学的組成物及びその製造方法 | |
US20200163882A1 (en) | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists | |
CA2684977C (en) | A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant | |
US20130011473A1 (en) | Preparation Method Of The Solid Formulation Of Clopidogrel Bisulfate | |
SI23290A (sl) | Nove oblike ivabradin hidroklorida | |
TWI736660B (zh) | 包含Akt蛋白質激酶抑制劑之醫藥組合物 | |
WO2008072534A1 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
TWI380829B (zh) | 具有改良的生物可利用率之普侖斯特(pranlukast)固態分散物組成物及製備該固態分散物之方法 | |
KR20090022616A (ko) | 베실산클로피도그렐 함유 경구투여용 약제 | |
EP3233059A1 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
EP2068838B1 (en) | Pharmaceutical formulations comprising clopidogrel | |
WO2016161991A2 (zh) | 一种硫酸氢氯吡格雷固体制剂及其制备方法 | |
JP5297194B2 (ja) | 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法 | |
KR20120127387A (ko) | 경구 투여용 의약 조성물 | |
KR101519612B1 (ko) | 옥스카르바제핀을 포함하는 방출 제어형 고체 제제의 제조 방법 및 그에 의해 얻어질 수 있는 제제 | |
KR100809903B1 (ko) | 안정화된 클로피도그렐-함유 입자, 그의 제조방법, 및 이를포함하는 약학 조성물 | |
CA2986522A1 (en) | Pharmaceutical compositions | |
KR20140022002A (ko) | 고형 의약 조성물 | |
CN106994121B (zh) | 一种用于治疗癌症的药物组合物 | |
CA2886276A1 (en) | Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof | |
WO2013091595A1 (en) | Pharmaceutical formulation of prasugrel hydrobromide | |
CN113304116A (zh) | 一种含有米诺膦酸的片剂及其制备方法 | |
KR20130103701A (ko) | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
KR101809886B1 (ko) | 소형화된 클래리트로마이신 경구투여 제제 | |
KR101944085B1 (ko) | 발사르탄 함유 고형 경구제형 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130902 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141119 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141215 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150310 |